University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Evaluating Primary Treatment for People with Advanced Glaucoma : Five-Year Results of the Treatment of Advanced Glaucoma Study

Simple item page
dc.contributor.authorKing, Anthony J
dc.contributor.authorHudson, Jemma
dc.contributor.authorAzuara-Blanco, Augusto
dc.contributor.authorBurr, Jennifer
dc.contributor.authorKernohant, Ashleigh
dc.contributor.authorHomer, Tara
dc.contributor.authorShabaninejad, Hosein
dc.contributor.authorSparrow, John M
dc.contributor.authorGarway-Heath, David
dc.contributor.authorBarton, Keith
dc.contributor.authorNorrie, John
dc.contributor.authorDavidson, Tracey
dc.contributor.authorVale, Luke
dc.contributor.authorMacLennan, Graeme
dc.contributor.authorTAGS Study Group
dc.contributor.institutionUniversity of Aberdeen.Centre for Healthcare Randomised Trials (CHaRT)en
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2024-07-16T10:44:01Z
dc.date.available2024-07-16T10:44:01Z
dc.date.issued2024-07-01
dc.descriptionFunding Information: The author(s) have made the following disclosure(s): The TAGS was supported by a Grant from the National Institute of Health and Care Research - Health Technology Assessment Program - 12/35/38. J.H.: Financial support – National Institute for Health Research Health Technology Assessment Programme. A.K.: Financial support – National Institute for Health Research Health Technology Assessment Programme T.H.: Financial support – National Institute for Health Research Health Technology Assessment Programme H.S.: Financial support – National Institute for Health Research Health Technology Assessment Programme J.M.S.: Financial support – National Institute for Health Research Health Technology Assessment Programme D.G.-H.: Consultant – AbbVie, Omikron, Santen, Roche; Financial support – National Institute for Health Research Health Technology Assessment Programme and Efficacy and Mechanism Evaluation (EME) Programme, MRC DPFS, Horizon 2020, Janssen R&D LLC, Santen; Royalties – Heidelberg Engineering; Lecturer – Viatris, Omikron, Novartis, AbbVie; Patent – UCL, Cardiff/UCL, City University of London; Leadership or fiduciary role – European Glaucoma Society, Glaucoma Research Society, Investigative Ophthalmology and Visual Science K.B.: Consultant – iStar, EyeDPharma, Laboratoires Thea, Advanced Ophthamic Innovations, ELT Sight, Sight Sciences, Shifamed/Myra Medical, Tarsier Pharma, Radiance TX; Financial support – Advanced Ophthamic Innovations, AISG, Ahtens Glaucoma Congress, Moroccan Glaucoma Society, ARPS - Singapore; Lecturer – Alcon, Allergan, Laboratoires Thea, Santen Pharmaceutical Co. Ltd.; Patent – National University of Singapore; Leadership or fiduciary role – ELT Sight; Equity owner – Vision Futures Limited, Vision Medical Events Ltd., Aquesys, MedEther Ophthalmology, International Glaucoma Surgery Registry J.N.: Financial support – National Institute for Health Research L.V.: Financial support – National Institute for Health Research Health Technology Assessment Programme G.M.: Financial support – National Institute for Health Research Health Technology Assessment Programme and EME Programme Obtained funding: N/Aen
dc.description.statusPeer revieweden
dc.format.extent12
dc.format.extent1072524
dc.identifier283949247
dc.identifierd765bcd5-648e-4c39-9c72-b21732e67953
dc.identifier38199528
dc.identifier85186194701
dc.identifier.citationKing, A J, Hudson, J, Azuara-Blanco, A, Burr, J, Kernohant, A, Homer, T, Shabaninejad, H, Sparrow, J M, Garway-Heath, D, Barton, K, Norrie, J, Davidson, T, Vale, L, MacLennan, G & TAGS Study Group 2024, 'Evaluating Primary Treatment for People with Advanced Glaucoma : Five-Year Results of the Treatment of Advanced Glaucoma Study', Ophthalmology, vol. 131, no. 7, pp. 759-770. https://doi.org/10.1016/j.ophtha.2024.01.007en
dc.identifier.doi10.1016/j.ophtha.2024.01.007
dc.identifier.iss7en
dc.identifier.issn0161-6420
dc.identifier.otherORCID: /0000-0002-1039-5646/work/153542678
dc.identifier.urihttps://hdl.handle.net/2164/23818
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85186194701&partnerID=8YFLogxKen
dc.identifier.vol131en
dc.language.isoeng
dc.relation.ispartofOphthalmologyen
dc.subjectIntraocular pressureen
dc.subjectOpen-angle glaucomaen
dc.subjectQuality of lifeen
dc.subjectRandomized controlled trialen
dc.subjectVisual field lossen
dc.subjectRE Ophthalmologyen
dc.subjectOphthalmologyen
dc.subjectSupplementary Dataen
dc.subjecthttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc1.pdfen
dc.subjecthttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc2.pdfen
dc.subjecthttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc3.pdfen
dc.subjecthttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc4.pdfen
dc.subject.lccREen
dc.titleEvaluating Primary Treatment for People with Advanced Glaucoma : Five-Year Results of the Treatment of Advanced Glaucoma Studyen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
King_etal_O_Evaluating_Primary_Treatment_VOR.pdf
Size:
1.02 MB
Format:
Adobe Portable Document Format
Download

Collections

All research